Amid all the tension in the wake of coronavirus crisis, University of Oxford’s potential Covid-19 vaccine has raised hopes as early trials have shown some positive results. Researchers at Oxford have discovered that their search for a coronavirus vaccine can might provide “double protection” against the novel virus, according to media reports in UK.
The vaccine has been licensed by AstraZenca and is already in large scale Phase 3rd human trials. Blood samples taken from a group UK volunteers during early trails, who were given a dose of the vaccine, showed that it can stimulate the body to provide antibodies as well as “Killer T-cells”. However, the developers have still not submitted the concluded report of the trails which would show whether it is safe or not.
It has been reported that developers saw some positive immune response of the vaccine in trails so far and will be publishing Phase 1 result by the end of July.
The vaccine has been supported the UK government and is probably in the most advanced stage as per the development.
According to the information received until now, the Oxford vaccine has shown the most promising results so far as it can produce killer T-cells as well as antibodies. While antibodies may fade away within months, T-cells circulation remains in the body for years.
AstraZeneca, meanwhile, has signed agreements with governments across the globe to supply the vaccine once it succeeds in its purpose.
The potential vaccine is one of the 100 vaccines being developed and tested around the world to stop the Covid-19 pandemic, which has taken away hundreds of thousands lives worldwide.
